在与临床前阿尔茨海默病血浆生物标记物的关联方面,自由回忆优于故事回忆

IF 4.3 Q2 BUSINESS
Andrew Aschenbrenner, J. J. Hassenstab, S. E. Schindler, S. Janelidze, O. Hansson, J. C. Morris, E. Grober
{"title":"在与临床前阿尔茨海默病血浆生物标记物的关联方面,自由回忆优于故事回忆","authors":"Andrew Aschenbrenner, J. J. Hassenstab, S. E. Schindler, S. Janelidze, O. Hansson, J. C. Morris, E. Grober","doi":"10.14283/jpad.2024.130","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>A decline in episodic memory is one of the earliest cognitive characteristics of Alzheimer disease and memory tests are heavily featured in cognitive composite endpoints that are used to demonstrate treatment efficacy. Assessments of episodic memory can take many forms including free recall, associate learning, and paragraph or story recall. Plasma biomarkers of Alzheimer disease are now widely available and will likely form the backbone of cohort enrichment strategies for future clinical trials. Thus, it is critical to evaluate which episodic memory measures are most sensitive to plasma markers of Alzheimer disease pathology.</p><h3 data-test=\"abstract-sub-heading\">Objectives</h3><p>To compare the associations of common episodic memory tests with plasma biomarkers of Alzheimer disease.</p><h3 data-test=\"abstract-sub-heading\">Design</h3><p>Longitudinal cohort study.</p><h3 data-test=\"abstract-sub-heading\">Setting</h3><p>Academic medical center in the midwestern United States.</p><h3 data-test=\"abstract-sub-heading\">Participants</h3><p>A total of 161 cognitively normal older adults with at least one plasma biomarker assessment and two or more annual clinical and cognitive assessments which included up to three different tests of episodic memory.</p><h3 data-test=\"abstract-sub-heading\">Measurements</h3><p>Episodic memory performance using free recall, paired associates recall or paragraph recall. Plasma Aβ42, Aβ40, ptau217, and neurofilament light chain were measured.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Free recall on the Free and Cued Selective Reminding Test with Immediate Recall (FCSRT + IR) was substantially more sensitive to longitudinal cognitive change associated with abnormal baseline plasma Aβ42/Aβ40 and ptau217 compared to other measures of episodic memory. A cognitive composite that included only free recall showed larger decline associated with baseline Aβ42/Aβ40 when compared to those that included paragraph recall. Differences in decline across composites were minimal when considering baseline ptau217 or NfL.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Episodic memory is a critical domain to assess in preclinical Alzheimer disease. Methods of assessing memory are not equal and longitudinal change in free recall substantially outperformed both paired associates and paragraph recall. Clinical trial results will depend critically on the episodic memory test(s) that are chosen for a composite endpoint and free recall from the FCSRT + IR is an optimal memory measure to include rather than paired associates or paragraph recall.</p>","PeriodicalId":22711,"journal":{"name":"The Journal of Prevention of Alzheimer's Disease","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Free Recall Outperforms Story Recall in Associations with Plasma Biomarkers in Preclinical Alzheimer Disease\",\"authors\":\"Andrew Aschenbrenner, J. J. Hassenstab, S. E. Schindler, S. Janelidze, O. Hansson, J. C. Morris, E. Grober\",\"doi\":\"10.14283/jpad.2024.130\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Background</h3><p>A decline in episodic memory is one of the earliest cognitive characteristics of Alzheimer disease and memory tests are heavily featured in cognitive composite endpoints that are used to demonstrate treatment efficacy. Assessments of episodic memory can take many forms including free recall, associate learning, and paragraph or story recall. Plasma biomarkers of Alzheimer disease are now widely available and will likely form the backbone of cohort enrichment strategies for future clinical trials. Thus, it is critical to evaluate which episodic memory measures are most sensitive to plasma markers of Alzheimer disease pathology.</p><h3 data-test=\\\"abstract-sub-heading\\\">Objectives</h3><p>To compare the associations of common episodic memory tests with plasma biomarkers of Alzheimer disease.</p><h3 data-test=\\\"abstract-sub-heading\\\">Design</h3><p>Longitudinal cohort study.</p><h3 data-test=\\\"abstract-sub-heading\\\">Setting</h3><p>Academic medical center in the midwestern United States.</p><h3 data-test=\\\"abstract-sub-heading\\\">Participants</h3><p>A total of 161 cognitively normal older adults with at least one plasma biomarker assessment and two or more annual clinical and cognitive assessments which included up to three different tests of episodic memory.</p><h3 data-test=\\\"abstract-sub-heading\\\">Measurements</h3><p>Episodic memory performance using free recall, paired associates recall or paragraph recall. Plasma Aβ42, Aβ40, ptau217, and neurofilament light chain were measured.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>Free recall on the Free and Cued Selective Reminding Test with Immediate Recall (FCSRT + IR) was substantially more sensitive to longitudinal cognitive change associated with abnormal baseline plasma Aβ42/Aβ40 and ptau217 compared to other measures of episodic memory. A cognitive composite that included only free recall showed larger decline associated with baseline Aβ42/Aβ40 when compared to those that included paragraph recall. Differences in decline across composites were minimal when considering baseline ptau217 or NfL.</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusion</h3><p>Episodic memory is a critical domain to assess in preclinical Alzheimer disease. Methods of assessing memory are not equal and longitudinal change in free recall substantially outperformed both paired associates and paragraph recall. Clinical trial results will depend critically on the episodic memory test(s) that are chosen for a composite endpoint and free recall from the FCSRT + IR is an optimal memory measure to include rather than paired associates or paragraph recall.</p>\",\"PeriodicalId\":22711,\"journal\":{\"name\":\"The Journal of Prevention of Alzheimer's Disease\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Prevention of Alzheimer's Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14283/jpad.2024.130\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BUSINESS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Prevention of Alzheimer's Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14283/jpad.2024.130","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BUSINESS","Score":null,"Total":0}
引用次数: 0

摘要

背景外显记忆衰退是阿尔茨海默病最早出现的认知特征之一,记忆测试在用于证明疗效的认知综合终点中占有重要地位。外显记忆的评估有多种形式,包括自由回忆、联想学习、段落或故事回忆。阿尔茨海默病的血浆生物标志物现已广泛应用,并可能成为未来临床试验队列富集策略的支柱。因此,评估哪些外显记忆测量方法对阿尔茨海默病病理血浆标志物最敏感至关重要。研究目的 比较常见外显记忆测试与阿尔茨海默病血浆生物标志物之间的关联。参与者 共有 161 名认知正常的老年人,他们至少接受过一次血浆生物标志物评估和两次或两次以上的年度临床和认知评估,其中包括多达三种不同的外显记忆测试。结果与其他外显记忆测量方法相比,自由回忆与即刻回忆选择性记忆测试(FCSRT + IR)对与基线血浆Aβ42/Aβ40和ptau217异常相关的纵向认知变化更为敏感。与包含段落回忆的认知综合指标相比,仅包含自由回忆的认知综合指标与基线 Aβ42/Aβ40 相关的下降幅度更大。在考虑基线 ptau217 或 NfL 时,不同综合指标的下降差异很小。评估记忆的方法不尽相同,自由回忆的纵向变化大大优于配对联想和段落回忆。临床试验结果很大程度上取决于为综合终点所选择的外显记忆测试,FCSRT + IR 的自由回忆是最佳的记忆测量方法,而不是配对联想或段落回忆。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Free Recall Outperforms Story Recall in Associations with Plasma Biomarkers in Preclinical Alzheimer Disease

Free Recall Outperforms Story Recall in Associations with Plasma Biomarkers in Preclinical Alzheimer Disease

Background

A decline in episodic memory is one of the earliest cognitive characteristics of Alzheimer disease and memory tests are heavily featured in cognitive composite endpoints that are used to demonstrate treatment efficacy. Assessments of episodic memory can take many forms including free recall, associate learning, and paragraph or story recall. Plasma biomarkers of Alzheimer disease are now widely available and will likely form the backbone of cohort enrichment strategies for future clinical trials. Thus, it is critical to evaluate which episodic memory measures are most sensitive to plasma markers of Alzheimer disease pathology.

Objectives

To compare the associations of common episodic memory tests with plasma biomarkers of Alzheimer disease.

Design

Longitudinal cohort study.

Setting

Academic medical center in the midwestern United States.

Participants

A total of 161 cognitively normal older adults with at least one plasma biomarker assessment and two or more annual clinical and cognitive assessments which included up to three different tests of episodic memory.

Measurements

Episodic memory performance using free recall, paired associates recall or paragraph recall. Plasma Aβ42, Aβ40, ptau217, and neurofilament light chain were measured.

Results

Free recall on the Free and Cued Selective Reminding Test with Immediate Recall (FCSRT + IR) was substantially more sensitive to longitudinal cognitive change associated with abnormal baseline plasma Aβ42/Aβ40 and ptau217 compared to other measures of episodic memory. A cognitive composite that included only free recall showed larger decline associated with baseline Aβ42/Aβ40 when compared to those that included paragraph recall. Differences in decline across composites were minimal when considering baseline ptau217 or NfL.

Conclusion

Episodic memory is a critical domain to assess in preclinical Alzheimer disease. Methods of assessing memory are not equal and longitudinal change in free recall substantially outperformed both paired associates and paragraph recall. Clinical trial results will depend critically on the episodic memory test(s) that are chosen for a composite endpoint and free recall from the FCSRT + IR is an optimal memory measure to include rather than paired associates or paragraph recall.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
The Journal of Prevention of Alzheimer's Disease
The Journal of Prevention of Alzheimer's Disease Medicine-Psychiatry and Mental Health
CiteScore
9.20
自引率
0.00%
发文量
0
期刊介绍: The JPAD Journal of Prevention of Alzheimer’Disease will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including: neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and heath economic outcomes.JPAD will publish also the meeting abstracts from Clinical Trial on Alzheimer Disease (CTAD) and will be distributed both in paper and online version worldwide.We hope that JPAD with your contribution will play a role in the development of Alzheimer prevention.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信